INSPIREMD INC. - COMMO

InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors

25 11 2024 16:05:00 提供 Nasdaq GlobeNewswire

InspireMD Reports Third Quarter 2024 Financial Results and Provides Business Update

12 11 2024 07:00:01 提供 Nasdaq GlobeNewswire

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

08 11 2024 17:30:03 提供 Nasdaq GlobeNewswire

InspireMD to Report Third Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, November 12th

04 11 2024 08:00:00 提供 Nasdaq GlobeNewswire

InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System

15 10 2024 07:00:00 提供 Nasdaq GlobeNewswire

InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System

07 10 2024 07:00:00 提供 Nasdaq GlobeNewswire

InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System

16 9 2024 07:00:00 提供 Nasdaq GlobeNewswire

InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update

06 8 2024 08:09:23 提供 Nasdaq GlobeNewswire

InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment

05 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th

30 7 2024 07:00:00 提供 Nasdaq GlobeNewswire

InspireMD Announces Full Exercise of Series H Warrant Tranche for Gross Proceeds of $17.9 Million

01 7 2024 07:00:00 提供 Nasdaq GlobeNewswire

InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024  

28 5 2024 08:53:00 提供 Nasdaq GlobeNewswire

InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update

14 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th

07 5 2024 07:00:01 提供 Nasdaq GlobeNewswire

InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference

03 4 2024 08:59:14 提供 Nasdaq GlobeNewswire

InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024

26 3 2024 07:00:00 提供 Nasdaq GlobeNewswire

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

06 3 2024 07:00:00 提供 Nasdaq GlobeNewswire

InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th

28 2 2024 07:00:00 提供 Nasdaq GlobeNewswire

InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System

12 2 2024 07:00:00 提供 Nasdaq GlobeNewswire

InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework

31 1 2024 07:00:00 提供 Nasdaq GlobeNewswire